First-in-class TACC3 inhibitor for solid tumours shows 80% CBR
Coiled Therapeutics has provided an update on its Phase I/II clinical trial evaluating AO-252, a first-in-class TACC3 inhibitor, in patients with advanced solid tumours.
According to the data, the transition to a Twice-Daily (BID) dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate (CBR), a significant improvement over the 40% CBR observed in the Once-Daily (QD) cohort.
A notable result has been observed in a leiomyosarcoma patient, who achieved Stable Disease after just two cycles of AO-252, despite having received nine prior lines of therapy.
A total of 80% of evaluable patients in the BID cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. This substantially outperforms the two-to-three-monthbenchmark typically seen with salvage therapy in this heavily pre-treated population.
AO-252 continues to demonstrate excellent tolerability with no serious adverse events observed to date.
The company is now accelerating the transition to targeted dose expansion cohorts in ovarian and prostate cancers, with an enrolment target of 40 patients by Q3 2026.
It says the emerging data confirms AO-252’s unique dual-action profile, combining direct cytotoxicity with immune-system activation via the cGAS/STING pathway.
Sridhar Vempati, Chief Executive Officer of Coiled Therapeutics, commented: “The data from Cohort 4b is transformative, achieving an 80% Clinical Benefit Rate and durable responses in such a heavily pre-treated patient population validates our BID dosing strategy and underscores the potential of TACC3 as a high value target in oncology.
“Furthermore, the emerging evidence of AO-252’s immune-modulatory activity positions it as a rare small molecule capable of engaging both direct tumour killing and immune activation. This would place AO-252 among a rare class of small molecules capable of engaging both direct cytotoxic and immune-activating mechanisms, considerably expanding its potential therapeutic applications and combination strategies.”
